Evolent Health, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 469.14 million compared to USD 319.94 million a year ago. Net loss was USD 34.32 million compared to USD 4.59 million a year ago. Basic loss per share from continuing operations was USD 0.37 compared to USD 0.05 a year ago. Basic loss per share was USD 0.37 compared to USD 0.05 a year ago.
For the six months, sales was USD 896.83 million compared to USD 617 million a year ago. Net loss was USD 54.31 million compared to USD 9.94 million a year ago. Basic loss per share from continuing operations was USD 0.62 compared to USD 0.11 a year ago. Basic loss per share was USD 0.62 compared to USD 0.11 a year ago.